Development and Evaluation of Ursolic Acid-loaded Poly(lactic--glycolic Acid) Nanoparticles in Cholangiocarcinoma

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2024 Aug 9

PMID 39119279

Authors

Pornpattra Maphanao

Yaowaret Phothikul

Cherdpong Choodet

Theerapong Puangmali

Kanlaya Katewongsa

Somchai Pinlaor

Raynoo Thanan

Umaporn Yordpratum

Chadamas Sakonsinsiri

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA), an epithelial biliary tract malignancy, is a significant health concern in the Greater Mekong Subregion, particularly in northeastern Thailand. Prior to the development of advanced stages, CCA is typically asymptomatic, thereby limiting treatment options and chemotherapeutic effectiveness. Ursolic acid (UA), a triterpenoid derived from plants, was previously discovered to inhibit CCA cell growth through induction of apoptosis. Nevertheless, the therapeutic effectiveness of UA is limited by its poor solubility in water and low bioavailability; therefore, dimethyl sulfoxide (DMSO) is utilized as a solvent to treat UA with CCA cells. Enhancing cellular uptake and reducing toxicity, the utilization of polymeric nanoparticles (NPs) proves beneficial. In this study, UA-loaded PLGA nanoparticles (UA-PLGA NPs) were synthesized using nanoprecipitation and characterized through formation analysis, average particle size, surface functional groups and -potential measurements, electron microscopic imaging, drug loading efficiency and drug release studies, stability, hemo- and biocompatibility, cytotoxicity and cellular uptake assays. Molecular dynamics simulations validated the loading of UA into PLGA hydrogen bonding. The synthesized UA-PLGA NPs had a spherical shape with an average size of 240 nm, a negative -potential, good stability, great hemo- and bio-compatibility and an encapsulation efficiency of 98%. The NPs exhibited a characteristic of a simple diffusion-controlled Fickian process, as predicted by the Peppas-Sahlin drug release kinetic model. UA-PLGA NPs exhibited cytotoxic effects on KKU-213A and KKU-055 CCA cells even when dispersed in media without organic solvent, , DMSO, highlighting the ability of PLGA NPs to overcome the poor water solubility of UA. Rhodamine 6G (R6G) was loaded into PLGA NPs using the same approach as UA-PLGA NPs, demonstrating effective delivery of the dye into CCA cells. These findings suggest that UA-PLGA NPs showed promise as a potential phytochemical delivery system for CCA treatment.

Citing Articles

Nanoencapsulation of vitamin B using chitosan-modified poly(lactic-co-glycolic acid) nanoparticles: Synthesis, characterization, and in vitro studies on simulated gastrointestinal stability and delivery.

Sathiensathaporn S, Sole-Porta A, Baowan D, Pissuwan D, Wongtrakoongate P, Roig A J Food Sci. 2024; 90(1):e17631.

PMID: 39731719 PMC: 11734382. DOI: 10.1111/1750-3841.17631.

References

Baishya R, Nayak D, Kumar D, Sinha S, Gupta A, Ganguly S . Ursolic Acid Loaded PLGA Nanoparticles: in vitro and in vivo Evaluation to Explore Tumor Targeting Ability on B16F10 Melanoma Cell Lines. Pharm Res. 2016; 33(11):2691-703. DOI: 10.1007/s11095-016-1994-1. View

Eckmann K, Patel D, Landgraf A, Slade J, Lin E, Kaur H . Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res. 2012; 4(5-6):155-60. PMC: 3269144. View

Takechi-Haraya Y, Ohgita T, Demizu Y, Saito H, Izutsu K, Sakai-Kato K . Current Status and Challenges of Analytical Methods for Evaluation of Size and Surface Modification of Nanoparticle-Based Drug Formulations. AAPS PharmSciTech. 2022; 23(5):150. PMC: 9122548. DOI: 10.1208/s12249-022-02303-y. View

Maphanao P, Thanan R, Loilome W, Chio-Srichan S, Wongwattanakul M, Sakonsinsiri C . Synchrotron FTIR microspectroscopy revealed apoptosis-induced biomolecular changes of cholangiocarcinoma cells treated with ursolic acid. Biochim Biophys Acta Gen Subj. 2020; 1864(12):129708. DOI: 10.1016/j.bbagen.2020.129708. View

Makadia H, Siegel S . Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2012; 3(3):1377-1397. PMC: 3347861. DOI: 10.3390/polym3031377. View

He L, Lai H, Chen T . Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways. Biomaterials. 2015; 51:30-42. DOI: 10.1016/j.biomaterials.2015.01.063. View

Elvevi A, Laffusa A, Scaravaglio M, Rossi R, Longarini R, Stagno A . Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022; 27(5):100737. DOI: 10.1016/j.aohep.2022.100737. View

Maeda O, Ebata T, Shimokata T, Matsuoka A, Inada-Inoue M, Morita S . Chemotherapy for biliary tract cancer: real-world experience in a single institute. Nagoya J Med Sci. 2020; 82(4):725-733. PMC: 7719462. DOI: 10.18999/nagjms.82.4.725. View

Wang X, Zhang F, Yang L, Mei Y, Long H, Zhang X . Ursolic acid inhibits proliferation and induces apoptosis of cancer cells in vitro and in vivo. J Biomed Biotechnol. 2011; 2011:419343. PMC: 3116524. DOI: 10.1155/2011/419343. View

10.

Weng H, Tan Z, Hu Y, Shu Y, Bao R, Jiang L . Ursolic acid induces cell cycle arrest and apoptosis of gallbladder carcinoma cells. Cancer Cell Int. 2014; 14(1):96. PMC: 4224689. DOI: 10.1186/s12935-014-0096-6. View

11.

Lopez-Hortas L, Perez-Larran P, Gonzalez-Munoz M, Falque E, Dominguez H . Recent developments on the extraction and application of ursolic acid. A review. Food Res Int. 2018; 103:130-149. DOI: 10.1016/j.foodres.2017.10.028. View

12.

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

13.

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

14.

Wozniak L, Skapska S, Marszalek K . Ursolic Acid--A Pentacyclic Triterpenoid with a Wide Spectrum of Pharmacological Activities. Molecules. 2015; 20(11):20614-41. PMC: 6332387. DOI: 10.3390/molecules201119721. View

15.

Tahir A, Plengsuriyakarn T, Chittasupho C, Na-Bangchang K . Potential of Alpha-Mangostin-Loaded PLGA Nanoparticles for Cholangiocarcinoma Treatment. Polymers (Basel). 2022; 14(20). PMC: 9607000. DOI: 10.3390/polym14204444. View

16.

Yurtdas Kirimlioglu G, Ozturk A . Levocetirizine Dihydrochloride-Loaded Chitosan Nanoparticles: Formulation and Evaluation. Turk J Pharm Sci. 2020; 17(1):27-35. PMC: 7227860. DOI: 10.4274/tjps.galenos.2018.34392. View

17.

Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M . Liver fluke induces cholangiocarcinoma. PLoS Med. 2007; 4(7):e201. PMC: 1913093. DOI: 10.1371/journal.pmed.0040201. View

18.

Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C . DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010; 12(3):263-71. PMC: 2895453. DOI: 10.1208/s12248-010-9185-1. View

19.

Markowski A, Jaromin A, Migdal P, Olczak E, Zygmunt A, Zaremba-Czogalla M . Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci. 2022; 23(10). PMC: 9143619. DOI: 10.3390/ijms23105536. View

20.

Gupta H, Aqil M, Khar R, Ali A, Bhatnagar A, Mittal G . Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine. 2009; 6(2):324-33. DOI: 10.1016/j.nano.2009.10.004. View